Tomoscan 370: peripheral arteriography, angiocardiography and left ventricular ventriculography, cerebral arteriography, retrograde aortography, selective renal arteriography, selective visceral angiography, digital subtraction angiography, excretory urography.
Composition and form of release
Active ingredient: iopamidol 612 mg / ml (equivalent to 300 mg / ml iodine) or 755 mg / ml (equivalent to 370 mg / ml iodine).
Tomoscan is available as a solution for injection.
It is an iodine-containing X-ray contrast agent. When administered intravascularly, it makes the blood flow opaque to X-rays, which provides radiographic visualization of the circulatory system.
Tomoscan 300 mg / ml is shown:
- for lumbar, thoracocervical myelography;
- for cerebral angiography;
- for peripheral angiography and venography;
- for contrast enhancement in computed tomography, arthrography, urography.
Tomoscan 370 mg / ml is shown:
- for peripheral arteriography;
- for angiocardiography;
- for carrying out left ventricular ventriculography;
- for cerebral arteriography;
- for carrying out retrograde aortography;
- for selective renal arteriography;
- for selective visceral angiography;
- for digital subtraction angiography;
- for excretory urography.
The drug Tomoscan is not used:
- with hypersensitivity to iodine-containing substances;
- in case of intolerance to excipients;
- with severe hyperthyroidism.
Apply with caution:
- in renal dysfunction;
- in diseases of the kidneys, liver;
- with homozygous sickle cell anemia;
- with multiple myeloma, other paraproteinemia;
- with anuria;
- in diabetes mellitus.
Use during pregnancy and breastfeeding
Studies do not indicate a direct or indirect negative impact on pregnancy, embryonic development, childbirth, postnatal development. However, sufficiently controlled studies have not been performed, so during pregnancy it is necessary to use the drug with extreme caution.
The ability of yoversol to be excreted in breast milk is unknown. But it is known that many injectable contrast agents are excreted unchanged in breast milk (approximately 1% of the administered dose). Although no adverse reactions have been identified, caution should be exercised when administering intravascularly to nursing patients. It is recommended to stop feeding for 24 hours.
Method of application and dose
Tomoscan is used according to the schemes in the instructions.
Apply the lowest dose that provides adequate visualization.
Overdose can be potentially life-threatening, manifested by cardiovascular and respiratory disorders.
Treatment is symptomatic, hemodialysis is indicated.
- Immune disorders: manifestations of allergies, including anaphylactoid reactions, anaphylactic shock.
- Mental disorders: agitation, confusion, anxiety.
- Neurological disorders: fainting, vertigo, tremor, headache, delirium, paresthesias, taste disturbances, loss of consciousness, speech impairment, paralysis, drowsiness, aphasia, stupor, dysphasia, hypoaesthesia, dyskinesia, convulsions, amnesia.
- Ophthalmic disorders: blurred vision, allergic conjunctivitis, eye irritation, tearing, redness, conjunctival edema, transient blindness.
- Otolaryngological disorders: ringing in the ears.
- Cardiovascular disorders: tachycardia, heart block, ECG changes, bradycardia, arrhythmia, angina, atrial fibrillation, cardiac arrest, coronary artery spasm, ventricular fibrillation, cyanosis, palpitations, extrasystole, hypertension / hypotension, hypotension, hypotension, hypotension phlebitis, vasodilation, vasospasm, shock, thrombosis, hemodynamic collapse.
- Respiratory disorders: laryngospasm, edema, airway obstruction, nasal congestion, stridor, shortness of breath, sneezing, cough, sore throat, pulmonary edema, hypoxia, pharyngitis, respiratory arrest, bronchospasm, apnea, asthma, dysphonia.
- Gastrointestinal disorders: dry mouth, nausea, sialadenitis, swelling of the tongue, abdominal pain, dysphagia, diarrhea, hypersalivation.
- Dermatological disorders: urticaria, rash, erythema, pruritus, Quincke’s edema, pallor, hyperhidrosis, toxic epidermal necrolysis.
- Musculoskeletal disorders: muscle cramps.
- Urinary disorders: involuntary urination, renal failure, decreased creatinine clearance, incontinence, hematuria, increased urea, dysuria, anuria, oliguria.
- General: fever, edema, pharyngeal edema, chills, tremor, changes in the injection site (pain, hemorrhage, erythema, necrosis), asthenic conditions, malaise, chest pain, hyperthermia.
Conditions and terms of storage
Store Tomoscan at a temperature up to +25 ° C for no more than three years.